EUVIMEDSkopri EUVIMED
Übersichtsarbeit

Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade

Dongdong Yu iD, Shuchan Li, Hao Chen, Lidong Wang

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70313 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation, 2025. Written by Dongdong Yu and 3 co-authors. Institution: Department of Orthopedic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, Immunotherapy. Cited 1 times so far (Crossref); 195 references. Funded by: Zhejiang Provincial Natural Science Foundation of China, Medical Health Science and Technology Project of Zhejiang Provincial Health Commission.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post‐transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor‐immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationImmunotherapyNeoplasm Recurrence, LocalHumansPrognosis

Author keywords

cellular cancer immunotherapyhepatocellular carcinomaliver transplantation

Authors and institutions

  • Department of Orthopedic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, China.
  • Department of Lung Transplantation and Thoracic Surgery, First Affiliated Hospital, University School of Medicine, Hangzhou, Zhejiang, China.
  • The Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, P.R. China.

ORCID profiles: Dongdong Yu

Funding

  • Zhejiang Provincial Natural Science Foundation of China
  • Medical Health Science and Technology Project of Zhejiang Provincial Health Commission

Cite

APA

Yu, D., Li, S., Chen, H., & Wang, L. (2025). Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade. Clinical Transplantation. https://doi.org/10.1111/ctr.70313

Vancouver

Yu D, Li S, Chen H, Wang L. Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade. Clinical Transplantation. 2025. doi:10.1111/ctr.70313

BibTeX
@article{Yu2025,
  author = {Yu, Dongdong and Li, Shuchan and Chen, Hao and Wang, Lidong},
  title = {Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70313}
}
Start for free →